50 results about "Epithelial carcinoma" patented technology

The invention provides a reagent for diagnosing cervical cancer, which can not only detect the presence or absence of cervical cancer but can also distinguish squamous cell carcinoma and adenocarcinoma from each other, a method for screening cervical cancer by using the reagent, particularly a screening method capable high speed processing by utilizing flow cytometry. The reagent comprises a first labeled antibody reacting with gland cells, a second labeled antibody reacting with adenocarcinoma cells and a third labeled antibody reacting with atypical cervical squamous cells, the antibodies being labeled with mutually distinguishable labels respectively. Preferably, at least one selected from the group consisting of MUC1 antibody, cytokeratin 7 antibody, and cytokeratin 18 antibody is used as the first labeled antibody, at least one selected from the group consisting of cytokeratin 8 antibody and HIK1083 antibody is used as the second labeled antibody, and at least one member selected from the group consisting of NMP179 antibody, p16[INK4A] antibody, Ki-67 antibody, p53 antibody, p21 antibody, EMA antibody, CEA antibody and MIB-1 antibody is used as the third labeled antibody.

The present invention relates to methods of prognosing urothelial carcinoma. In one embodiment, the present invention provides a method of prognosing urothelial carcinoma by determining expression levels of JUN, MAP2K6, STAT3 and / or ICAM1. In another embodiment, the present invention provides an single prognostic panel made up of eight gene markers. In another embodiment, the present invention provides a single prognostic panel made up of eleven gene markers.

A flaviviral replicon-based construct is provided for delivery and expression of granulocyte-macrophage colony stimulating factor to facilitate tumour therapy. In particular, the replicon construct encodes a Kunjin virus replicon having one or more mutations in an NS2A non-structural protein that induce enhanced levels of cellular IFN that synergize with recombinant granulocyte-macrophage colony stimulating factor delivered according to the invention. The construct may be administered intra-tumourally or peri-tumourally to an animal as DNA, RNA or packaged into a VLP, for the therapeutic and / or prophylactic treatment of tumours and cancers such as melanoma, lung carcinoma, cervical carcinoma, lung epithelial carcinoma, prostate cancer, breast cancer, renal carcinoma, colon cancer, epithelial cancers and mesothelioma.

The invention relates to the field of biotechnology and medical diagnosis, in particular to a detection method and a kit for diagnosing bladder urothelium carcinoma. The invention provides application of a primer combination for detecting a DNA methylation difference region in a to-be-detected sample in preparation of a reagent or a kit for detecting or predicting whether a subject suffers from bladder urinary tract epithelial carcinoma or not or whether a bladder urinary tract epithelial carcinoma patient typing is muscular layer wetting or non-muscular layer wetting or not. The invention also relates to a kit for detecting or predicting whether a subject suffers from the bladder urothelial carcinoma or whether a bladder urothelial carcinoma patient typing is muscular layer infiltration or non-muscular layer infiltration. The detection method and the kit for diagnosing the bladder urinary tract epithelium cancer, provided by the invention, have excellent sensitivity and specificity, have great positive significance on clinical diagnosis and treatment of the bladder urinary tract epithelium cancer and later monitoring and prognosis evaluation, and provide a theoretical basis for further early diagnosis.

The invention relates to methods for locally delivering a chemotherapeutic agent to an upper tract urothelial carcinoma (UTUC). The methods involve placing a balloon catheter that has a working channel and a balloon into the ureter / renal pelvis via retrograde or antegrade ureteral access; inflating the catheter balloon to temporarily obstruct the ureter; infusing (instilling) a liposomal formulation that includes a chemotherapeutic agent into the working channel of the catheter; and allowing the infused liposomal formulation to dwell in the ureter and / or renal pelvis for a time sufficient to allow at least a portion of the liposomal formulation to adhere to the urothelial wall. In the methods of the invention, at least a portion of the infused chemotherapeutic-agent formulation adheres tothe urothelial wall while it is instilled and dwells in the ureter and / or renal pelvis. The disclosed methods can be performed as an adjuvant therapy to other methods of treating UTUC, such as ureteroscopic ablation or resection of the tumor.

The invention relates to 4-deoxidized-iso-podophyllotoxin derivatives displayed by formula (1) and the intermediate series of compounds of 4-deoxidized-iso-podophyllotoxin derivatives or the pharmaceutical salt or solvates of the 4-deoxidized-iso-podophyllotoxin derivatives. The invention also relates to the preparation method, the drug combinations, and the pharmaceutical applications of compounds in the formula (1). The compounds possess strong activity in inhibiting tumor cell growth, some of which having stronger cytotoxic activity to human body tumor cell lines in vitro than etoposide, the prior first class anti-tumor drug, thereby the compounds are expected to serve the purpose of such cancer drugs as anti-lung cancer drugs, anti-hepatoma drugs, and anti-cerbical cancer drugs; since the cytotoxicity of the related compounds to KB cells and PC-3 cells is approximate to or equivalent to etoposide, and meanwhile the compounds have strong etoposide to CNE cells, the compounds are expected to used in anti-tumor drugs, such as, anti-oral epithelial carcinoma drugs, nasopharyngeal carcinoma drugs, and prostate cancer drugs.

The present invention provides methods, devices, and kits related to treatment of urothelial carcinomas of the lower tract with antimetabolite (such as gemcitabine). In some aspects the methods, devices and kits relate to treatment of urothelial carcinomas of the lower tract with an antimetabolite (such as gemcitabine) and an immunomodulating agent.

The invention discloses a siRNA sequence for inhibiting survivin gene expression. The siRNA sequence has a broad spectrum siRNA antitumor effect, and has a good inhibitory effect on breast cancer, lung cancer, colon cancer, liver cancer, leukemia, gastric carcinoma, cervical cancer, oral epithelial carcinoma in vitro, and particularly on breast cancer, lung cancer and cervical cancer cells. When entering an organism through a certain manner, the siRNA double strand sequence can efficiently and specially inhibit the expression of related proteins of diseases to silence related disease protein, and can effectively remove the expression of target gene to achieve the purpose of treatment.

This invention relates to methods of distinguishing among various types of differentiated and undifferentiated epithelial carcinomas, and non-epithelial carcinomas, by detecting the presence of p63 nucleic acid or protein expression. The invention also provides methods for detecting p63 nucleic acids and proteins, as well as methods for diagnosing and treating certain tumors based on whether the tumors express p63.

The present invention provides a monoclonal antibody for recognizing HPV16-positive cervical epithelial cancer cells and its application. The antibody can detect cervical cancer biomarker HPV16E7 protein in tumor cells with high specificity, thereby being able to distinguish cancerous cervical epithelial cells from cervical abnormalities Or non-cancerous cervical epithelial cells, providing evidence for doctors to accurately diagnose cancer caused by HPV infection, can effectively reduce the missed diagnosis rate of high-grade cervical lesions, provide sufficient time and basis for clinicians to diagnose and treat patients, and improve early cervical disease detection and early intervention. At the same time, unnecessary colposcopy can also be reduced and avoided.

Described herein methods of treating urothelial carcinoma with an approved drug product containing a fibroblast growth factor receptor (FGFR) inhibitor. Also described herein are methods of selling or offering for sale an approved drug product containing a fibroblast growth factor receptor (FGFR) inhibitor.

The invention discloses a urine detection kit for diagnosing urothelium carcinoma. The urine detection kit comprises capture reagent, detection reagent, coating buffer solution, scrubbing solution, color-producing reagent and termination reagent. The capture reagent is anti-Neu5Gc primary antibody, and the detection agent is anti-Neu5Gc second antibody. The kit disclosed by the invention is high in sensitivity and has the advantage of the urine exfoliocytology, the problem that the urine exfoliocytology is low in sensitivity is overcome, and the kit can be used for the early screening of the urothelium carcinoma.

The invention relates to a homogeneous immunoassay reagent kit for detecting beta human chorionic gonadotropin in the technical field of immunoassay, and a preparation method and application thereof. The homogeneous immunodetection reagent kit for β-human chorionic gonadotropin obtained by the method provided by the present invention has a wide range of signal values ​​when analyzed by the photo-excited chemiluminescence immunoassay platform, and reaches the quantitative test standard; the sensitivity is high, and can be accurately detected. The serum or urine β-hCG level is used for in vitro diagnosis; it has good stability and high precision; and by optimizing the analysis system (antibody dosage and buffer solution, etc.), the analysis performance meets the industry standard, which is used for clinical pregnancy diagnosis and dynamic monitoring of hydatidiform mole and hydatidiform mole. Provide reference for the therapeutic effect of choriocarcinoma.

The invention relates to the discovery and application of a plurality of drug lead compounds, in particular to a bis-substituted allyl benzene compound with cytotoxic activity, the key intermediate and the pharmaceutical salt of the compound, also to the preparation method, the drug composition and the medicinal purpose of the allyl benzene derivative and the key intermediate of the allyl benzenederivative, belonging to the fields of organic chemistry, medicinal chemistry and pharmacology. The compound of the discovery in vitro inhibits the activity of six human tumor cell lines-human prostate cancer cells (PC-3), nasopharyngeal carcinoma cells (CNE), oral epithelial carcinoma cells (KB), human lung cancer cells (A549), human hepatoma cells (BEL-7404) and human cervical cancer cells (Hela), and can be expected for antitumor drug purpose.

The present invention provides a monoclonal antibody for identifying high-risk HPV E7-positive cervical epithelial cancer cells and its application. The antibody can detect cervical cancer biomarker HPV E7 protein in tumor cells with high specificity, covering high-risk HPV16, HPV31, HPV35, High-risk subtypes such as HPV52 and HPV58 can distinguish cancerous cervical epithelial cells from cervical abnormalities or non-cancerous cervical epithelial cells, providing evidence for doctors to accurately diagnose cancers caused by HPV infection, and can effectively reduce the missed diagnosis rate of high-grade cervical lesions , provide sufficient time and basis for clinicians to diagnose and treat patients, and improve early detection and early intervention of cervical diseases. At the same time, unnecessary colposcopy can also be reduced and avoided.